DUBLIN, Ireland, September 11, 2015 (LifeSiteNews) – A global pharmaceutical company has agreed to help “underserved” women by giving discounts on IUDs to abortion businesses and health clinics.
In a press release, Allergan announced it will grant discounts to Apexus, the vendor for its products, in order to “expand access to IUDs for millions of underserved women throughout the United States who may not have been able to afford one.”
Apexus is releasing Allergan's IUD, named LILETTA, an intrauterine “contraceptive” that acts as an abortifacient, for nationwide distribution.
The abortion industry is applauding Allergan's “charitable” help for poor mothers. “We are committed to increasing access and reducing cost barriers to IUD use,” said Herm Cukier, vice president of women's health care at Allergan. “Our partnership with Apexus plays a key role in fulfilling that commitment.”
“We are committed to helping … deliver health care services to underserved patients and enabling them to treat more patients in need through discounted pharmaceuticals and value-added services,” said Lisa Sokol, vice president of marketing and customer service for Apexus.
“Making LILETTA more accessible … helps protect health and empower patients,” Sokol said. “We are proud to do our part.”
Thousands of LILETTA IUDs have been shipped to U.S. health departments, abortion businesses, and Indian Health Service clinics.
Jim Sedlak, vice president of American Life League, said: “This IUD can cause the death of an already created human being by inhibiting implantation. Are women being told that by having this device inserted in their body, they could be ending the lives of their sons and daughters?”
Click “like” if you are PRO-LIFE!
“Our experience,” Sedlak continued, “is that women are not being informed. Pushing LILETTA IUDs for insertion, especially in young people, is outrageous and must be stopped.”
Stephen Phelan of Human Life International commented, “We know why pharmaceutical companies like Allergan and resellers like Planned Parenthood push this kind of nonsense. What is harder to understand is why more physicians are not demanding that this assault on poor women is stopped in its tracks.”
In its promotional materials, Allergan admits, “Some serious complications with … LILETTA are sepsis, perforation, and expulsion. Severe infection or sepsis … have been reported following insertion of other … [IUD]s.”
Their own warnings include “The likelihood of a pregnancy being ectopic is increased with LILETTA” and “Spotting and irregular or heavy bleeding may occur during the first 3 to 6 months.”
The long list of warnings continues: “Perforation (total or partial, including penetration/embedment of LILETTA in the uterine wall or cervix) may occur, most often during insertion, although the perforation may not be detected until sometime later,” Allergan admits. “Surgery may be required.”
“Delayed detection or removal of LILETTA in case of perforation may result in migration outside the uterine cavity, adhesions, peritonitis, intestinal perforations, intestinal obstruction, abscesses, and erosion of adjacent viscera,” the warnings read. “Ovarian cysts may occur and … may be accompanied by pelvic pain or dyspareunia.”
In the clinical trial of LILETTA, 27 percent of women suffered infections. Others experienced nausea, vomiting, dyspareunia, abdominal pain, breast pain, pelvic pain, depression, mood changes, migraine headaches, and acne.
“Ask any OB-GYN if a woman will have better health outcomes if, all other things being equal, she fills her body full of hormones, or if she avoids the hormones,” Phelan reasoned. “Add to this the fact that the woman who takes these hormones is also told that it is now safer to engage in behavior that comes with a whole host of other risks that are not mitigated by the hormones.”
“Every physician will tell you that a woman is better off not taking the hormones and learning to avoid risky sexual behavior.”
Allergan, which has commercial operations in 100 countries, is teaming up with San Francisco's Medicines360, an abortifacient company “with a mission to expand access to quality medicines for all women.”
“Medicines360 is committed to working with healthcare providers, advocacy groups and patients to deliver innovative and meaningful treatments that help women around the world have greater choice and access to the medicines they need.”